Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.
Article Details
- CitationCopy to clipboard
Yang W, Hu Y, Yang YS, Zhang F, Zhang YB, Wang XL, Tang JF, Zhong WQ, Zhu HL
Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.
Bioorg Med Chem. 2013 Mar 1;21(5):1050-63. doi: 10.1016/j.bmc.2013.01.013. Epub 2013 Jan 16.
- PubMed ID
- 23391364 [ View in PubMed]
- Abstract
Two series of novel naphthalin-containing pyrazoline derivatives C1-C14 and D1-D14 have been synthesized and evaluated for their EGFR/HER-2 inhibitory and anti-proliferation activities. Compound D14 displayed the most potent activity against EGFR and A549 cell line (IC(50)=0.05 muM and GI(50)=0.11 muM), being comparable with the positive control Erlotinib (IC(50)=0.03 muM and GI(50)=0.03 muM) and more potent than our previous compounds C0-A (IC(50)=5.31 muM and GI(50)=33.47 muM) and C0-B (IC(50)=0.09 muM and GI(50)=0.34 muM). Meanwhile, compound C14 displayed the most potent activity against HER-2 and MCF-7 cell line (IC(50)=0.88 muM and GI(50)=0.35 muM), being a little less potent than Erlotinib (IC(50)=0.16 muM and GI(50)=0.08 muM) but far more potent than C0-A (IC(50)=6.58 muM and GI(50)=27.62 muM) and C0-B (IC(50)=2.77 muM and GI(50)=3.79 muM). The docking simulation was performed to analyze the probable binding models and the QSAR models were built for reasonable design of EGFR/HER-2 inhibitors at present and in future. The structural modification of introducing naphthalin moiety reinforced the combination of our compounds and the receptor, resulting in progress of bioactivity. Moreover, the replacement of thiourea skeleton by using benzene ring resulted in the slight diversity of the two series towards specific targets.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Erlotinib Epidermal growth factor receptor IC 50 (nM) 30 N/A N/A Details